Patient requires systemic, pharmacologic doses of corticosteroids (equivalent to > mg hydrocortisone/day) Note: Replacement doses (equivalent to ?  mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as needed
Physiologic doses of corticosteroids are permitted (i.e., no more than  mg of prednisone daily)
Existing significant autoimmune conditions; patients with a history of Hashimoto thyroiditis who are stable on replacement hormone therapy are not excluded; patients cannot be on long-term (>  weeks) corticosteroids at doses exceeding prednisone  mg (or its equivalent) prior to enrollment; short-term corticosteroid dosing is permitted as long as steroids are discontinued within  weeks of study enrollment
Must not have required immunosuppressive agents, other than corticosteroids for the management of an adverse event and not currently requite maintenance doses of > milligrams (mg) prednisone (or equivalent) per day.
Is on chronic systemic steroid therapy in excess of replacement doses (prednisone ?  mg/day is acceptable), or on any other form of immunosuppressive medication. For CTCL, continued use of either prednisone ? mg/day or continued use of topical steroids is acceptable.
Require systemic pharmacologic doses of corticosteroids greater than the equivalent of  mg/day prednisone; topical, ophthalmologic and inhalational steroids are permitted. Subjects who have a history of adrenal insufficiency and are receiving greater than  mg/day prednisone may be eligible but only after Sponsor consultations. Subjects who are currently receiving steroids at a dose of ?  mg/day do not need to discontinue steroids prior to enrollment
Systemic corticosteroid therapy within  days before enrollment. Note: Topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed. ?  mg/day of prednisone or equivalent doses of other corticosteroids are not allowed.
Subjects with immunotherapy related adverse events requiring high doses of steroids (?  mg/day of prednisone) are not eligible.
Have Eastern Cooperative Oncology Group (ECOG) performance status of  or  on stable or reducing dose of steroids for symptom management (not more than  mg of dexamethasone or equivalent per day) for  days prior to enrollment; change in glucocorticoid dose for any purpose other than to modulate symptoms from an adverse event; Note: The use of physiologic doses (e.g., prednisone  mg) of corticosteroids may be approved after consultation with Merck & Co; use of prophylactic corticosteroids to avoid allergic reactions (e.g. IV contrast dye) is permitted
Concomitant use of systemic corticosteroids at physiologic doses or >  mg/day of prednisone or equivalent
The treating physician expects that the patient will not require more than physiologic replacement dose of steroids defined as  mg of cortisone per day or its equivalent
Current use of corticosteroid therapy >  mg/day of prednisone or equivalent doses of other corticosteroids (topical, intranasal, and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed)
Patients must not take corticosteroids including prednisone, dexamethasone or any other corticosteroid for  days before apheresis and CAR T-cell infusion; patients must also not take corticosteroids at doses higher than  mg/day of prednisone or equivalent at any time after the CAR T cell infusion
Patients receiving chronic, high dose systemic treatment with corticosteroids defined as: chronic use of cortisone > mg; hydrocortisone > mg, prednisone > mg, methylprednisone > mg or dexamethasone > .mg; or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Subjects requiring escalating or chronic supraphysiologic doses of corticosteroids (>  mg/d of prednisone equivalent) for control of disease at the time of registration
Therapeutic doses of corticosteroids (defined as > mg/day prednisone or equivalent) within  days of leukapheresis or  hours prior to JCAR administration. Physiologic replacement, topical, and inhaled steroids are permitted.
CELL PROCUREMENT: Prior to procurement current use of systemic corticosteroids at doses >= mg/day prednisone or its equivalent; those receiving < mg/day may be enrolled at discretion of investigator; (Note: corticosteroid use with doses at the discretion of the treating physician are allowed after procurement up to the beginning of lymphodepletion; corticosteroid use is contraindicated following iC-CAR infusion unless medically necessary e.g., to treat CRS)\r\n* Physiologic replacement with hydrocortisone is allowed at doses - mg/m^/day, or equivalent
LYMPHODEPLETION: Use of systemic corticosteroids at doses >= mg/day prednisone or its equivalent; those receiving < mg/day may be enrolled at discretion of investigator; (Note: Corticosteroid use with doses at the discretion of the treating physician are allowed after procurement up to the beginning of lymphodepletion)\r\n* Physiologic replacement with hydrocortisone is allowed at - mg/m/day, or equivalent
Requirement for concomitant high dose corticosteroids\r\n* EXCEPTION: Patients may be on chronic steroids (maximum dose  mg/day prednisone equivalent) if they are being given for adrenal insufficiency, rheumatoid arthritis, etc
No steroids are permitted within  days of CD; or doses <  mg/day prednisone equivalent or levels necessary for physiologic replacement
Concomitant disease which requires continuous therapy with corticosteroids at doses equivalent to prednisolone > mg/day.
Must not have required the use of additional immunosuppressive agents other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > milligrams prednisone or equivalent per day.
PRIOR TO LYMPHODEPLETION: Current use of systemic corticosteroids at doses ?  mg prednisone daily or its equivalent; those receiving <  mg daily may be enrolled at discretion of investigator; inhaled steroids are allowed\r\n* For pediatric patients, physiologic replacement hydrocortisone at doses - mg/m^/day is allowed; equivalently dosed alternative steroids are allowed at discretion of investigator, though not to exceed mg prednisone per day; inhaled steroids are allowed
PRIOR TO INFUSION OF ATLCAR.CD CELLS: Current use of systemic corticosteroids at doses ?  mg prednisone daily or its equivalent; those receiving <  mg daily may be enrolled at discretion of investigator; inhaled steroids are allowed\r\n* For pediatric patients, physiologic replacement hydrocortisone at doses -mg/m^/day is allowed; equivalently dosed alternative steroids are allowed at discretion of investigator, though not to exceed mg prednisone per day; inhaled steroids are allowed
Patients must not take corticosteroids including prednisone, dexamethasone or any other corticosteroid for  days before apheresis and CAR T-cell infusion; patients must also not take corticosteroids at doses higher than  mg/day of prednisone or equivalent at any time after the CAR T cell infusion
Subject requires escalating or chronic supraphysiologic doses of corticosteroids >  mg dexamethasone or equivalent
Other concurrent immunotherapy (eg, immunosuppressants or chronic use of systemic corticosteroids, with the exception that low-dose corticosteroids [ mg/day prednisone or equivalent corticosteroid] are allowed; these should be discussed with the Medical Monitor)
Must not have a concurrent medical condition requiring use of systemic corticosteroids with prednisone >  mg per day
Systemic corticosteroids <  week prior to Day  in Phase a. Subjects may receive stable physiologic replacement doses of glucocorticoids (up to the equivalent of  mg daily prednisone) as maintenance therapy for adrenal insufficiency.
Study-Specific Exclusion\r\n* Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study\r\n* History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab\r\n* Dependence on corticosteroids:\r\n** If the participant is undergoing leukapheresis: physiological replacement doses of steroids are allowed - prednisone no more than . mg, hydrocortisone less than  mg.m^/day\r\n*** However, all participants must be able to reduce steroid requirement to no more than physiological replacement doses prior to start of lymphodepletion\r\n* Active autoimmune disease requiring systemic immunosuppressive therapy
Dependence on corticosteroids\r\n* Steroid dependence can be defined as a medical need to be greater than  mg of prednisone (or equivalent doses of other systemic steroids) a day, chronically; higher doses need to be avoided for at least  days prior to leukapheresis and, again, for at least  days prior to T cell infusion and up to at least  months after T cell infusion unless medically indicated to treat a new toxicity\r\n* Note: topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed
Dependence on corticosteroids\r\n* Defined as doses of corticosteroids of greater than  mg/day of prednisone or equivalent doses of other corticosteroids\r\n* Note: topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed\r\n* Please note that this criterion is not applicable if the research participant's donor is undergoing leukapheresis
Medical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than  mg/day or equivalent)
Able to be off of corticosteroids and any other immune suppressive medications beginning on day - and continuing until  days after the infusion of the CIML NK cells; however, use of low-level corticosteroids is permitted if deemed medically necessary; low-level corticosteroid use is defined as  mg or less of prednisone (or equivalent for other steroids) per day
Have not received any leukemia treatment within  week prior to starting study drug; corticosteroids up to  mg of prednisone (or equivalent) is allowable throughout the study; doses >  mg prednisone (or equivalent) are NOT permitted; doses of steroids =<  mg of prednisone (or equivalent) are permitted; hydroxyurea is allowed prior to enrollment and after the start of the study drug for the control of peripheral leukemic blasts in subjects with leukocytosis per physician discretion
Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within  days prior to first dose of study treatment. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to  mg per day of hydrocortisone or up to  mg per day of prednisone) are allowed.
Systemic corticosteroids at physiologic doses ? mg/day of prednisone or equivalent are permitted;
Chronic treatment for more than  months with systemic corticosteroids at doses above  mg prednisolone or equivalent before study entry
Medical condition requiring any form of chronic systemic immunosuppressive therapy (steroid or other) except physiologic replacement doses of hydrocortisone or equivalent (no more than  mg hydrocortisone or  mg prednisone equivalent daily) for <  days duration.
REGISTRATION TO TREATMENT (STEP ): No current use of corticosteroids; EXCEPTION: Low doses of steroids (<  mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permitted
REGISTRATION TO TREATMENT (STEP ): No current use of corticosteroids; EXCEPTION: Low doses of steroids (<  mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permitted
Concomitant high dose corticosteroids except patients may be on chronic steroids (maximum dose  mg/day prednisone equivalent) if they are being given for disorders other than myeloma, e.g. adrenal insufficiency, rheumatoid arthritis, etc
Requires escalating or chronic supraphysiologic doses of corticosteroids (>  mg/day prednisone equivalents)
History of severe asthma, as defined by prior or current use of systemic corticosteroids for disease control, with the exception of physiological replacement doses of cortisone acetate or equivalent, as defined by a dose of  mg or less
Concurrent systemic immunosuppressive therapy or steroid therapy with more than  consecutive days of steroids within the last  weeks\r\n* The use of prednisone or equivalent < . mg/kg/day (absolute maximum of  mg/day) as replacement therapy is permitted\r\n* Inhaled corticosteroids are permitted\r\n* The following will not be exclusionary:\r\n** The presence of laboratory evidence of autoimmune disease (e.g. positive antinuclear antibody [ANA] titer) without associated symptoms\r\n** Mild Raynauds phenomenon\r\n** History of severe asthma, as defined by prior or current use of systemic corticosteroids for disease control, with the exception of physiological replacement doses of cortisone acetate or equivalent, as defined by a dose of prednisone or equivalent of  mg or less
No systemic cytotoxic chemotherapy within  weeks of enrollment or systemic steroids (except stable doses of prednisone =<  mg/day, or up to  doses of steroid given for non-therapy reasons) within  weeks of enrollment
Other anti-platelet agents; Aspirin use at doses up to  milligrams (mg)/day is permitted.
Requires treatment with high dose systemic corticosteroids defined as > mg/day
Patients receiving corticosteroids for any indication within  days before the onset of acute GVHD, except the following: Stable replacement doses of corticosteroids for adrenal insufficiency are permitted (e.g. hydrocortisone total dose of - mg/m^/day or prednisone -.mg daily or equivalent). Corticosteroids administered as premedication before transfusion of blood products or before intravenous medications to prevent infusion reactions are allowed.
Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent;
Subjects with Immunotherapy related adverse events requiring high doses of steroids (?  mg/day of prednisone) are not eligible
Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent
Requirement for chronic immunosuppressive medication including systemic corticosteroids above the physiologic dose ( mg/day hydrocortisone or the equivalent).
Requires escalating or chronic supraphysiologic doses of corticosteroids (>  mg/day prednisone equivalents)
Steroids (at prednisone equivalent doses >  mg) are not permitted  days prior to T cell infusion and concurrently during therapy. Exceptions include use of systemic prednisone equivalent doses =<  mg/ day, topical steroids or physiologic replacement dose of steroids for adrenocortical deficiency.
Patient has a medical condition that requires chronic systemic steroid therapy or requires any other form of immunosuppressive medication; however, patients using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study; up to  mg hydrocortisone (or  mg of prednisone) in the morning and  mg hydrocortisone (or . mg of prednisone) in the evening
Patients must be on a stable or decreasing dose of corticosteroids for  days prior to enrollment; patient may be taking therapeutic doses of steroids during the initial dose escalations and prior to defining an RPD; this should be recorded in the database; once the RPD has been established, enrollment may be limited based on steroid use;*physiologic replacement doses will be defined on this protocol as no more than . mg/m^/day of dexamethasone or equivalent of steroids; doses higher than this will be considered therapeutic
Concurrent therapy with approved or investigational anticancer therapeutic; patients are allowed to receive corticosteroids for the treatment of non-malignant disorders in doses not to exceed the equivalent of prednisone  mg/day
Physiologic doses of corticosteroids are allowed (i.e. no more than  mg prednisone daily)
Dependence on corticosteroids\r\n* Defined as doses of corticosteroids of greater than or equal to  mg/day of prednisone or equivalent doses of other corticosteroids\r\n* Note: topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed
No current use of corticosteroids; EXCEPTION: low doses of steroids (<  mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permitted
Patients with medical conditions that require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication. However, patients using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study: up to  mg hydrocortisone (or  mg of prednisone) in the morning and  mg hydrocortisone (or . mg prednisone) in the evening.
Therapeutic doses of corticosteroids (defined as >  mg/day prednisone or equivalent) within  days prior to leukapheresis
No medical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than  mg/day or equivalent)
Concomitant high dose corticosteroids other than what is part of treatment protocol (concurrent use of corticosteroids); EXCEPTION: patients may be on chronic steroids (maximum dose  mg/day prednisone equivalent) if they are being given for disorders other than myeloma, i.e., adrenal insufficiency, rheumatoid arthritis, etc
Current use of systemic corticosteroids (>  mg prednisone)
Use of systemic corticosteroids in doses greater than prednisone equivalent to  mg/day.
Current use of corticosteroids; EXCEPTION: low doses of steroids (=<  mg of prednisone or equivalent dose of other steroid) used for treatment of nonhematologic medical conditions; NOTE: previous use of corticosteroids is allowed
if receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than  mg of dexamethasone a day or equivalent, i.e.  mg prednisone or  mg hydrocortisone for at least  days prior to date of enrollment.
Patient requiring systemic, pharmacologic doses of corticosteroids (equivalent to >  mg hydrocortisone/day or  mg dexamethasone/day). Replacement doses (equivalent to ?  mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as needed.
Patient requires systemic, pharmacologic doses of corticosteroids (equivalent to >  mg hydrocortisone/day or  mg dexamethasone/day). Replacement doses (equivalent to ?  mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as needed.
Concomitant high dose corticosteroids (concurrent use of corticosteroids); EXCEPTION: patients may be on chronic steroids (maximum dose  mg/day prednisone equivalent) if they are being given for disorders other than amyloid, i.e., adrenal insufficiency, rheumatoid arthritis, etc.
Doses ?  mg/day prednisolone or equivalent is allowed, provided that the steroid dose has been stable or tapering for at least  days prior to the first dose of CA-
Supraphysiologic doses of glucocorticoids (defined as >  mg of hydrocortisone per day or > . mg of Prednisone per day, or equivalent doses of other agents) or exposure to other immunosuppressive medications in the previous  days.
Concomitant high dose corticosteroids (concurrent use of corticosteroids) while on single agent ibrutinib; EXCEPTION: patients may be on chronic steroids (maximum dose  mg/day prednisone equivalent) if they are being given for disorders other than amyloid, (i.e., adrenal insufficiency, rheumatoid arthritis, etc)
Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =<  mg or  mg equivalent prednisone per day
Chronic use of steroids at immunosuppressive doses. (Note, physiologic replacement doses of glucocorticoid or mineralocorticoid are acceptable, eg. prednisone - mg/day; fludrocortisone .-. mg/day)
Current use of systemic corticosteroids at doses > mg/day prednisone or its equivalent; those receiving =< mg may be enrolled at discretion of investigator
Require systemic pharmacologic doses of corticosteroids at or above the equivalent of  mg/d prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted. Subjects who have a history of adrenal insufficiency and are receiving greater than  mg/day systemic steroids may be eligible but only after Sponsor consultation.
